HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Hemostatic Disorders

Subscribe to New Research on Hemostatic Disorders

Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS.

Also Known As:

Hemostatic Disorders, Vascular; Disorder, Vascular Hemostatic; Disorders, Vascular Hemostatic; Hemostatic Disorder; Hemostatic Disorder, Vascular; Vascular Hemostatic Disorder; Vascular Hemostatic Disorders

Networked: 129 relevant articles (4 outcomes, 5 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hemophilia A (Haemophilia)
2.	von Willebrand Diseases (von Willebrand's Disease)
3.	Menorrhagia
4.	Acute Promyelocytic Leukemia
5.	Pulmonary Tuberculosis

Experts

1.	Lubnin, A Iu: 2 articles (07/2010 - 05/2009)
2.	Stepanenko, A Iu: 2 articles (07/2010 - 05/2009)
3.	Israelian, L A: 2 articles (07/2010 - 05/2009)
4.	Lippi, Giuseppe: 2 articles (10/2009 - 08/2006)
5.	Franchini, Massimo: 2 articles (10/2009 - 08/2006)
6.	Balinger, Kathryn J: 1 article (12/2015)
7.	Arantes, Eliane Candiani: 1 article (12/2015)
8.	de Pauw, Edwin: 1 article (12/2015)
9.	de Melo Rodrigues, Veridiana: 1 article (12/2015)
10.	Anasti, James N: 1 article (12/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hemostatic Disorders:

1.	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 01/01/1994 - "Evaluation of desmopressin for dental extractions in patients with hemostatic disorders." 01/01/2002 - "In this article the possibility of using the Minirin (desmopressin) in maxillofacial surgery in person with hemostatic disorders has been described. " 10/01/1990 - "Desmopressin may be useful in the treatment of hemostatic disorders such as von Willebrand's disease and hemophilia A. " 10/01/1990 - "Desmopressin for diabetes insipidus, hemostatic disorders and enuresis." 09/01/1992 - "1-Deamino-8 D-arginine vasopressin (DDAVP) has been used effectively to normalize the bleeding time in various hemostatic disorders. "
2.	Arginine Vasopressin (Argipressin)IBA 09/01/1992 - "1-Deamino-8 D-arginine vasopressin (DDAVP) has been used effectively to normalize the bleeding time in various hemostatic disorders. "
3.	rituximab (Mabthera)FDA Link 08/01/2006 - "The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders."
4.	Blood Coagulation Factors (Coagulation Factor)IBA 03/01/1978 - "With clinical vigilance and laboratory tests of platelet and coagulation factor function, the clinician can promptly recognize and treat hemostatic disorders in leukemic patients. " 12/01/2013 - "Secondary hemostatic disorders (congenital or acquired deficiencies of coagulation factors) typically manifest with delayed, deep bleeding into muscles and joints. " 05/01/2012 - "Von Willebrand disease is the most common primary hemostatic disorder in dogs, and hemophilia A is the most common coagulation factor disorder. " 03/01/2011 - "The purpose of the investigation was to study an association of hemostatic disorders in diabetic patients with methylenetetrahydrofolate reductase (MTHFR) (C677T) and coagulation factors II (G20210A) and V (G1691A) gene polymorphism. " 03/01/2011 - "[Association of hemostatic disorders in diabetic patients with methylenetetrahydrofolate reductase (C677T) and coagulation factors II (G20210A) and V (G1691A) gene polymorphism]."
5.	Thromboplastin (Tissue Factor)IBA 06/01/1992 - "Molecules that induce tissue factor expression by responsive cells such as endothelial cells and monocytes may be important in the regulation of hemostasis and, perhaps, in mediating certain hemostatic disorders. " 10/01/2008 - "A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor." 08/15/2012 - "The potentially fatal hemostatic disorder of disseminated intravascular coagulation (DIC) is initiated in bacterial sepsis by lipopolysaccharide (LPS)-induced tissue factor (TF) expression on monocytes. " 03/01/2000 - "To study in vivo effect of all-trans-retinoic acid (ATRA) or arsenic trioxide (As2O3) on the expression of tissue factor (TF) and the hemostatic disorders, a series of parameters were measured in bone marrow blasts and plasma from acute promyelocytic leukemia (APL) patients. "
6.	FibrinIBA 07/01/1996 - "Role of fibrin sealants in surgical procedures on patients with hemostatic disorders." 07/01/1995 - "The utilization of fibrin sealants in patients with hemostatic disorders has hitherto been very limited. " 01/01/1988 - "Elective procedures of fibrin identification were employed to study morphological signs of hemostatic disorders in the material obtained from 20 autopsies for lung cancer. " 09/01/2003 - "However, there are several unique hemostatic derangements associated with lymphoproliferative disorders that express paraproteins and these are the subject of this article (eg, inhibition of fibrin polymerization, qualitative platelet dysfunction, acquired von Willebrand factor deficiency, heparin-like circulating anticoagulants, light chain amyloid associated hemostatic disorders, acquired coagulation factor deficiencies, and acquired hypercoagulable states). "
7.	Levonorgestrel (Plan B)FDA LinkGeneric 09/01/2008 - "Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders." 10/01/2005 - "The study was undertaken to evaluate the levonorgestrel-releasing intrauterine system (LNG-IUS) in managing menorrhagia associated with hemostatic disorders. " 09/01/2008 - "To evaluate the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in women with known hemostatic disorders and abnormal uterine bleeding. " 10/01/2005 - "The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders."
8.	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 03/01/2011 - "The purpose of the investigation was to study an association of hemostatic disorders in diabetic patients with methylenetetrahydrofolate reductase (MTHFR) (C677T) and coagulation factors II (G20210A) and V (G1691A) gene polymorphism. " 03/01/2011 - "[Association of hemostatic disorders in diabetic patients with methylenetetrahydrofolate reductase (C677T) and coagulation factors II (G20210A) and V (G1691A) gene polymorphism]."
9.	Tretinoin (Retinoic Acid)FDA LinkGeneric 03/01/2000 - "To study in vivo effect of all-trans-retinoic acid (ATRA) or arsenic trioxide (As2O3) on the expression of tissue factor (TF) and the hemostatic disorders, a series of parameters were measured in bone marrow blasts and plasma from acute promyelocytic leukemia (APL) patients. "
10.	arsenic trioxide (Trisenox)FDA Link 03/01/2000 - "To study in vivo effect of all-trans-retinoic acid (ATRA) or arsenic trioxide (As2O3) on the expression of tissue factor (TF) and the hemostatic disorders, a series of parameters were measured in bone marrow blasts and plasma from acute promyelocytic leukemia (APL) patients. "

Therapies and Procedures

1.	Hemodilution 09/01/1985 - "Hemodilution was shown to be an effective means of controlling hemostatic disorders in coronary patients, hemostatic normalization being accompanied with clinical improvement in part of the cases."
2.	Plasmapheresis 09/01/2009 - "The paper gives the methods of plasmapheresis-based extracorporeal exposure to blood and its components to correct hemostatic disorders. " 01/01/2007 - "The purpose of the investigation was to study the efficiency of small-volume plasmapheresis in the correction of hemostatic disorders in patients with progressive destructive pulmonary tuberculosis. " 01/01/2007 - "[Experience with small-volume plasmapheresis used in the correction of hemostatic disorders in patients with progressive destructive pulmonary tuberculosis]."
3.	Liver Transplantation 01/01/2008 - "To measure the variations of different parameters in the hemostatic system and to analyze their roles in the development of hemostatic disorder in patients with orthotopic liver transplantation (OLT) procedures routinely performed without venovenous bypass. " 10/01/2010 - "Introduction of fibrinogen in the treatment of hemostatic disorders during orthotopic liver transplantation: implications in the use of allogenic blood."
4.	Resuscitation 12/01/2015 - "Treatment is based on an interdisciplinary approach that consists of a combination of prompt, aggressive hemodynamic resuscitation, provision of end-organ support, correction of hemostatic disorders, and delivery. " 08/01/1992 - "Dilution of the circulating blood volume from pump perfusate and volume resuscitation with crystalloid and colloid solutions produce fluid, electrolyte, and hemostatic disorders. "
5.	Drug Therapy (Chemotherapy) 08/31/2007 - "Their implication for preventive and curative pharmacotherapy of hemostatic disorders is presented, with discussion of related problems." 02/01/2010 - "Cytotoxic chemotherapy induces or worsens hemostatic disorders in patients with acute myeloid leukemia. "